Cambridge Investment Research Advisors, Inc. Atai Life Sciences N.V. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 13,020 shares of ATAI stock, worth $20,962. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,020
Previous 13,045
0.19%
Holding current value
$20,962
Previous $15,000
13.33%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ATAI
# of Institutions
104Shares Held
16.3MCall Options Held
367KPut Options Held
69.2K-
Morgan Stanley New York, NY3.33MShares$5.36 Million0.0% of portfolio
-
Ubs Group Ag1.94MShares$3.12 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.31MShares$2.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny982KShares$1.58 Million0.0% of portfolio
-
Davidson Kempner Capital Management LP New York, NY949KShares$1.53 Million0.03% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $267M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...